Akademik Veri Yönetim Sistemi
ESMO OPEN, cilt.9, sa.9, ss.9-10, 2024 (SCI-Expanded)
Background: Non-clear cell renal cell carcinoma (non-ccRCC) is a highly heterogeneous disease group, accounting for approximately 25% of all RCC cases. Due to its
rarity and especially heterogeneity, phase III trial data is limited and treatment options generally follow those of clear cell RCC. In the literature, there exists a number
of studies with sunitinib, cabozantinib, and everolimus, but data on the efficacy of
pazopanib are limited. Our aim in this study was to compare the efficacy of pazopanib
and sunitinib, in a multicenter retrospective cohort of non-ccRCC patients.
Methods: Our study included patients diagnosed with non-ccRCC who received
pazopanib or sunitinib treatment as first-line therapy from 22 tertiary hospitals. We
compared the progression-free survival (PFS), overall survival (OS), and response rates
of pazopanib and sunitinib treatments. Additionally, we investigated prognostic factors in non-ccRCC.
Results: PFS and response rates of sunitinib and pazopanib were found to be similar,
while a numerical difference was observed in OS. Being 65 years and older, being in
the intermediate or poor risk group according to the International Metastatic Renal
Cell Carcinoma Database Consortium, having liver metastases, presence of a sarcomatoid component, and having de novo metastatic disease were found to be
significantly associated with shorter PFS.
Conclusions: Pazopanib treatment appears to have similar efficacy in the treatment of
non-ccRCC compared to sunitinib. As we know from ccRCC studies, pazopanib has
better tolerability than sunitinib. Though randomized controlled trials are lacking and
will probably be never be available, we suggest that pazopanib could be a preferred
agent like sunitinib and cabozantinib